For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Shionogi Inks Malaria Drug Collab with Nagasaki University, MMV
March 14, 2023
- Serious Side Effect Cases Total 8: Xocova Safety Update
March 13, 2023
- Padcev Application Accepted for Review in China: Astellas
March 13, 2023
- AstraZeneca Looks to 1st IO/ADC Launch as Leader in the Race: Oncology Head
March 13, 2023
- Eisai Eyes 1 Trillion Yen in Leqembi Global Sales in FY2030: CEO
March 10, 2023
- Xospata Fails in PIII for Post-Transplant AML Maintenance Therapy: Astellas
March 10, 2023
- Shingo Iwamoto Sworn in as New Chief of Nichi-Iko; Tamura Bows Out
March 9, 2023
- Silgard 9 Approved for 2-Dose Schedule: MSD
March 9, 2023
- Nipro Curbed Shipments of 28 APIs/40 Products as Precaution for Rush Demand
March 9, 2023
- Opdivo Tops Japan Drug Ranking for 14 Months Running: Encise
March 8, 2023
- Japan Ethical Drug Sales Grow 3.5% in January: Crecon
March 8, 2023
- Teva Takeda Prepping for Listing of Allermist AG in June
March 8, 2023
- Kyorin Out-Licenses Vibegron to Sumitomo in 5 Asian Markets
March 7, 2023
- Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
March 7, 2023
- Drug Makers Wary of Rush Demand Tied to Unprofitability Re-Pricing, Some Curb Orders
March 7, 2023
- Teijin Grants Global Rights for Kidney Disease Med to Novartis
March 7, 2023
- FDA Accepts Eisai’s Lecanemab Application for Early July Target
March 6, 2023
- Generic Makers See Milder Cuts in FY2023 Revision, Nipro to Get 1%-Plus Net Hike: Jiho Poll
March 6, 2023
- 2023 Price Cut for Top-Tier, 2nd-Tier Firms at 1-4%, Tsumura Only Original Drug Maker to See Net Rise: Jiho Poll
March 6, 2023
- Sumitomo Pharma Drops Cancer Drug Candidate Dubermatinib
March 6, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…